Results 211 to 220 of about 37,032,341 (244)
Senotherapeutics for Knee Osteoarthritis
Medicinal Research Reviews, EarlyView.ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman +6 more
wiley +1 more source
Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance
Medicinal Research Reviews, EarlyView.ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi +4 more
wiley +1 more source
Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor [PDF]
Molecular Pharmacology, 2011 The ability of dopamine receptors to interact with other receptor subtypes may provide mechanisms for modulating dopamine-related functions and behaviors. In particular, there is evidence suggesting that the trace amine-associated receptor 1 (TAAR1) affects the dopaminergic system by regulating the firing rate of dopaminergic neurons or by altering ...
Stefano Espinoza +2 more
exaly +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Trace Amine-Associated Receptor 1 Agonists for Schizophrenia
Canadian Journal of Health Technologies, 2022TAAR1 agonists are an emerging drug class in the treatment of schizophrenia as they may offer a novel mechanism of action for symptom management without blocking dopamine D2 receptors, unlike currently available antipsychotic medications that act primarily via D2 binding. Two TAAR1 agonists are currently in clinical development for schizophrenia.
Christopher Vannabouathong +2 more
openaire +1 more source
Trace amine associated receptor 1 and movement control
Parkinsonism & Related Disorders, 2008The recently discovered trace amine associated receptors (TAARs) represent attractive potential mediators of certain aspects of movement control. The TAAR that is best characterized, TAAR1, is particularly interesting because it can be activated by a variety of monoaminergic compounds including trace amines, amphetamines and dopamine metabolites.
Tatyana D, Sotnikova +4 more
openaire +2 more sources
Trace Amine-Associated Receptor 1 Is a Modulator of the Dopamine Transporter
The Journal of Pharmacology and Experimental Therapeutics, 2007Trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor activated by a broad range of monoamines and amphetamine-related psychostimulants. Recent studies demonstrated wide distribution of TAAR1 in brain, coexpression of TAAR1 with dopamine transporter (DAT) in a subset of dopamine neurons in both mouse and rhesus monkey substantia ...
Zhihua, Xie, Gregory M, Miller
openaire +2 more sources
Activation of trace amine-associated receptor 1 ameliorates PTSD-like symptoms
Biochemical PharmacologyTrace amine-associated receptor 1 (TAAR1) negatively modulates monoaminergic transmission in the mammalian brain and participates in many psychiatric disorders. Preclinical evidence indicate that selective TAAR1 agonists have anxiolytic effects and anti-stress properties.
Linlin Peng +9 more
openaire +2 more sources